Aquestive Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AQST research report →
Range $10 – $11
Price Chart
About the company
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome.
- CEO
- Daniel Barber
- IPO
- 2018
- Employees
- 147
- HQ
- Warren, NJ, US
Get TickerSpark's AI analysis on AQST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $434.88M
- P/E
- -5.78
- Fwd P/E
- 9.23
- PEG
- -1.39
- P/S
- 9.52
- P/B
- 0.00
- EV/EBITDA
- -5.91
- Div Yield
- 0.00%
- Gross Margin
- 65.34%
- Op Margin
- -114.12%
- Net Margin
- -162.33%
- ROE
- 255.11%
- ROIC
- -54.28%
Latest fiscal year · YoY change
- Revenue
- $44.55M-22.6%
- Gross Profit
- $27.39M-31.0%
- Op Income
- $-69,650,279
- Net Income
- $-83,784,000-89.8%
- EPS
- $-0.76-49.0%
- OCF Growth
- -46.6%
- FCF Growth
- -47.5%
- 52W High
- $6.74
- 52W Low
- $2.93
- 50D MA
- $4.23
- 200D MA
- $4.22
- Beta
- 1.50
- RSI (14)
- 36
- Avg Volume
- 2.41M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Aquestive said it is on track for an ANNAFILM FDA decision, has strengthened its balance sheet, and is preparing for a potential 2027 launch while monetizing Libervant through an out-licensing deal.· November 4, 2026
- ANNAFILM resubmission was filed before the end of Q3, and management is now focused on the FDA review with a March 16, 2027 decision date.
- The company out-licensed Libervant to Eton, receiving a $10 million upfront payment, potential milestone payments of up to $47.5 million, and a mid-teens royalty.
- Cash was $90.3 million at 9/30/2026, and management still expects to end 2026 with more than $70 million in cash and cash equivalents.
- Full-year 2026 guidance was maintained at $46 million to $50 million of revenue and a non-GAAP adjusted EBITDA loss of $35 million to $30 million.
- Management emphasized a focused launch plan: about 75 reps, roughly 8,000 to 8,500 targets, and payer discussions already underway.
Total revenue in Q3 2026 was $7.6 million versus $12.8 million in Q3 2025, with the decline driven mainly by lower Suboxone orders. Manufacturer and supplier revenue was $6.7 million versus $11.5 million a year ago; license and royalty revenue was $800 thousand versus $1 million; and codevelopment and research fees were about $100 thousand versus about $300 thousand. Q3 net loss was $16.5 million, or $0.13 per basic and diluted share, versus a net loss of $15.4 million, or $0.14 per share, in Q3 2025; non-GAAP adjusted EBITDA loss was $12.2 million versus $8.6 million a year ago. For the first nine months of 2026, total revenue rose 14% to $35.8 million, net loss was $47.4 million, and non-GAAP adjusted EBITDA loss narrowed to $19.2 million. Management maintained full-year 2026 guidance for total revenue of $46 million to $50 million and non-GAAP adjusted EBITDA loss of $35 million to $30 million.
Daniel Barber framed the quarter as an execution story, repeatedly saying the company delivered on the milestones it had promised: the ANNAFILM resubmission, the Libervant out-license, debt refinancing, and a year-end cash target above $70 million. He emphasized that ANNAFILM is the lead asset, described the FDA timeline as uncertain but stayed with the March 16, 2027 action date, and said the team is preparing for a spring launch if approved. His tone was confident and operationally focused, with repeated emphasis on speed of response, payer engagement, and building a commercial organization that can support launch and future pipeline growth.
Ernie Toth focused on financial discipline and liquidity. He highlighted the $10 million upfront payment from Eton, up to $47.5 million in additional milestones, and a mid-teens royalty, while noting Aquestive remains the exclusive manufacturer and supplier of Libervant. He said cash and cash equivalents were $90.3 million at 9/30/2026, excluding the October Eton payment, and reiterated that year-end cash should exceed $70 million even without assuming contingent RTW or Oaktree funding. He also confirmed the company is holding full-year guidance at $46 million to $50 million in revenue and a non-GAAP adjusted EBITDA loss of $35 million to $30 million.
Analysts pressed on ANNAFILM launch plans, payer access, and whether the FDA review would be narrow or effectively from scratch. Management said the resubmission scope should be limited to the complete response items, and that pre-approval discussions with PBMs are important because the company wants to show the clinical data behind the product’s differentiation. Questions also focused on commercial targeting versus Neffy; management said the launch will be highly targeted at allergists and other key high-prescribing specialists, with about 75 reps calling on roughly 8,000 to 8,500 physicians. On manufacturing, management said FDA inspection activity remains possible and that the company is prepared if the agency wants to inspect the manufacturing site.
The company appears to have cleared several execution hurdles on schedule and still has more than $70 million of expected year-end cash, giving it room to prepare for an ANNAFILM launch if approved. Management also sounded confident that the product’s differentiation is based on clinical speed and pharmacodynamic response, and it believes payers and clinicians can be convinced by that data. The Libervant deal adds non-dilutive capital and preserves future royalties while management focuses on ANNAFILM and the pipeline.
ANNAFILM still depends on FDA approval, and management acknowledged it does not control the timeline even though it is aiming for March 16, 2027. Commercial access is still uncertain because management said it must persuade PBMs to cover a premium product, and pricing was not disclosed. The launch will also require disciplined spending, payer wins, and uptake in a market where auto-injectors have long dominated, while the company’s base business remains important but not a growth driver.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 90.0%
- Shares Outstanding
- 125.69M
- Float Shares
- 113.18M
of shares held by institutions
195 13F filers
Buy/sell ratio 2.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bratton Capital Management, L.P. | 9.81M | 0 |
| Blackrock, Inc. | 8.21M | ▲ 143.99K |
| Rtw Investments, LP | 7.43M | 0 |
| Vanguard Group Inc | 5.89M | ▲ 230.20K |
| Vanguard Capital Management LLC | 4.78M | ▲ 199.67K |
| State Street Corp | 3.48M | ▲ 553.37K |
| Federated Hermes, Inc. | 3.20M | ▲ 85.30K |
| Geode Capital Management, LLC | 2.90M | ▲ 272.75K |
| Samsara Biocapital, LLC | 2.50M | 0 |
| Hrt Financial LP | 1.80M | ▲ 1.46M |
| Bank Of America Corp | 1.67M | ▼ 736.63K |
| Sio Capital Management, LLC | 1.49M | ▼ 436.71K |
Held by 145 ETFs
Biggest fund positions in AQST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Davis Matthew W. | sell | 7,197 |
| Nov 10, 26 | Daly Richard J | buy | 26,825 |
| Nov 10, 26 | Daly Richard J | buy | 1,200 |
| Nov 10, 26 | Davis Matthew W. | other | 5,303 |
| Nov 6, 26 | Daly Richard J | other | 57,000 |
| Oct 21, 26 | Cochran John | other | 62,229 |
| Oct 15, 26 | Barber Daniel | sell | 25,000 |
| Oct 15, 26 | Daly Richard J | other | 0 |
| Sep 15, 26 | Barber Daniel | sell | 25,000 |
| Sep 9, 26 | Korczynski Sherry | other | 8,750 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AQST coverage
Recent articles, reports, and earnings notes.
No research on AQST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AQST report →Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 18
Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
marketbeat.com · Nov 16
Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
globenewswire.com · Nov 9
Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
globenewswire.com · Nov 5
Traders Purchase Large Volume of Put Options on Aquestive Therapeutics (NASDAQ:AQST)
defenseworld.net · Nov 5
Aquestive Therapeutics, Inc. (AQST) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 4
What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
marketbeat.com · Nov 4
Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
zacks.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.